Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes.

Zaccaria GM, Ferrero S, Rosati S, Ghislieri M, Genuardi E, Evangelista A, Sandrone R, Castagneri C, Barbero D, Lo Schirico M, Arcaini L, Molinari AL, Ballerini F, Ferreri A, Omedè P, Zamò A, Balestra G, Boccadoro M, Cortelazzo S, Ladetto M.

JCO Clin Cancer Inform. 2019 Oct;3:1-15. doi: 10.1200/CCI.19.00049.

2.

Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy.

Cereda E, Turri A, Klersy C, Cappello S, Ferrari A, Filippi AR, Brugnatelli S, Caraccia M, Chiellino S, Borioli V, Monaco T, Stella GM, Arcaini L, Benazzo M, Grugnetti G, Pedrazzoli P, Caccialanza R.

Cancer Med. 2019 Sep 30. doi: 10.1002/cam4.2517. [Epub ahead of print]

3.

Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.

Varettoni M, Boveri E, Zibellini S, Tedeschi A, Candido C, Ferretti VV, Rizzo E, Doni E, Merli M, Farina L, Goldaniga M, Gallì A, Rattotti S, Frustaci AM, Deodato M, Bandiera L, Isimbaldi G, Uccella S, Cabras AD, Gianelli U, Baldini L, Paulli M, Arcaini L.

Am J Hematol. 2019 Nov;94(11):1193-1199. doi: 10.1002/ajh.25600. Epub 2019 Sep 9.

PMID:
31378966
4.

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.

Luminari S, Merli M, Rattotti S, Tarantino V, Marcheselli L, Cavallo F, Varettoni M, Bianchi B, Merli F, Tedeschi A, Cabras G, Re F, Visco C, Torresan Delamain M, Cencini E, Spina M, Ferrero S, Ferrari A, Deodato M, Mannina D, Annibali O, Rago A, Orsucci L, Defrancesco I, Frigeni M, Cesaretti M, Arcaini L.

Blood. 2019 Sep 5;134(10):798-801. doi: 10.1182/blood.2019001088. Epub 2019 Jul 10.

PMID:
31292118
5.

A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.

Varettoni M, Zibellini S, Boveri E, Klersy C, Candido C, Rattotti S, Ferretti VV, Defrancesco I, Mangiacavalli S, Nizzoli ME, Flospergher E, Zerbi C, Bergamini F, Benvenuti P, Brociner M, Merati G, Paulli M, Arcaini L.

Br J Haematol. 2019 Jul 5. doi: 10.1111/bjh.16086. [Epub ahead of print]

PMID:
31276195
6.

Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.

Cocito F, Mangiacavalli S, Valeria Ferretti V, Cartia CS, Ganzetti M, Benveuti P, Pompa A, Catalano M, Fugazza E, Landini B, Arcaini L, Corso A.

Leuk Lymphoma. 2019 Jun 6:1-7. doi: 10.1080/10428194.2019.1620948. [Epub ahead of print]

PMID:
31169049
7.

ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center.

Iovino P, Scudeller L, Ferretti VV, Arcaini L, Dellafiore F.

Creat Nurs. 2019 May 1;25(2):157-168. doi: 10.1891/1078-4535.25.2.157.

PMID:
31085671
8.

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.

Rumi E, Zibellini S, Boveri E, Cavalloni C, Riboni R, Casetti IC, Ciboddo M, Trotti C, Favaron C, Pietra D, Candido C, Ferretti VV, Cazzola M, Arcaini L.

Am J Hematol. 2019 Jul;94(7):E185-E188. doi: 10.1002/ajh.25489. Epub 2019 May 1. No abstract available.

PMID:
30972817
9.

The Possible Role of Gut Microbiota and Microbial Translocation Profiling During Chemo-Free Treatment of Lymphoid Malignancies.

Zuccaro V, Lombardi A, Asperges E, Sacchi P, Marone P, Gazzola A, Arcaini L, Bruno R.

Int J Mol Sci. 2019 Apr 9;20(7). pii: E1748. doi: 10.3390/ijms20071748. Review.

10.

Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).

Rusconi C, Anastasia A, Chiarenza A, Marcheselli L, Cavallo F, Rattotti S, Botto B, Ferrari A, Nassi L, Pagani C, Meli E, Arcaini L, Federico M, Rossi G; Fondazione Italiana Linfomi (FIL).

Br J Haematol. 2019 May;185(4):713-717. doi: 10.1111/bjh.15816. Epub 2019 Feb 21.

PMID:
30793297
11.

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Rattotti S, Ferretti VV, Rusconi C, Rossi A, Fogazzi S, Baldini L, Pioltelli P, Balzarotti M, Farina L, Ferreri AJM, Laszlo D, Speziale V, Varettoni M, Sciarra R, Morello L, Tedeschi A, Frigeni M, Defrancesco I, Zerbi C, Flospergher E, Nizzoli ME, Morra E, Arcaini L; “Rete Ematologica Lombarda” (REL - Hematology Clinical Network of Lombardy - Lymphoma Workgroup).

Hematol Oncol. 2019 Apr;37(2):160-167. doi: 10.1002/hon.2575. Epub 2019 Feb 22.

PMID:
30726562
12.

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.

Merli M, Frigeni M, Alric L, Visco C, Besson C, Mannelli L, Di Rocco A, Ferrari A, Farina L, Pirisi M, Piazza F, Loustaud-Ratti V, Arcari A, Marino D, Sica A, Goldaniga M, Rusconi C, Gentile M, Cencini E, Benanti F, Rumi MG, Ferretti VV, Grossi P, Gotti M, Sciarra R, Tisi MC, Cano I, Zuccaro V, Passamonti F, Arcaini L.

Oncologist. 2019 Aug;24(8):e720-e729. doi: 10.1634/theoncologist.2018-0331. Epub 2018 Dec 14.

PMID:
30552159
13.

Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk.

Caccialanza R, Cereda E, Caraccia M, Klersy C, Nardi M, Cappello S, Borioli V, Turri A, Imarisio I, Lasagna A, Saddi J, Arcaini L, Benazzo M, Stragliotto S, Zagonel V, Pedrazzoli P.

Support Care Cancer. 2019 Jul;27(7):2497-2506. doi: 10.1007/s00520-018-4527-0. Epub 2018 Nov 1.

PMID:
30387050
14.

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K.

Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.

15.

Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications.

Ciammella P, Luminari S, Arcaini L, Filippi AR.

Hematol Oncol. 2018 Dec;36(5):723-732. doi: 10.1002/hon.2538. Epub 2018 Aug 26. Review.

PMID:
30146794
16.

Benefits and risks of JAK inhibition.

Arcaini L, Cazzola M.

Blood. 2018 Aug 16;132(7):675-676. doi: 10.1182/blood-2018-07-858720. No abstract available.

PMID:
30115632
17.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.

PMID:
29984825
18.

Diagnosis and management of prefibrotic myelofibrosis.

Rumi E, Sant'Antonio E, Boveri E, Pietra D, Cavalloni C, Roncoroni E, Astori C, Arcaini L; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Expert Rev Hematol. 2018 Jul;11(7):537-545. doi: 10.1080/17474086.2018.1484280. Epub 2018 Jun 22. Review.

PMID:
29862872
19.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL.

Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

20.

MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR.

Haematologica. 2018 Sep;103(9):e408-e411. doi: 10.3324/haematol.2018.190181. Epub 2018 Mar 29. No abstract available.

21.

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V.

Haematologica. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22.

22.

Overview on the management of non-gastric MALT lymphomas.

Defrancesco I, Arcaini L.

Best Pract Res Clin Haematol. 2018 Mar;31(1):57-64. doi: 10.1016/j.beha.2017.11.001. Epub 2017 Nov 14. Review.

PMID:
29452667
23.

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trnĕný M; SPRINT Trial Investigators.

Br J Haematol. 2018 Jan;180(2):224-235. doi: 10.1111/bjh.15025. Epub 2017 Nov 28.

24.

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M.

J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.

PMID:
29095677
25.

From hepatitis C virus infection to B-cell lymphoma.

Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, Canioni D, Michot JM, Visco C, Arcaini L, Besson C, Hermine O.

Ann Oncol. 2018 Jan 1;29(1):92-100. doi: 10.1093/annonc/mdx635.

PMID:
29045541
26.

Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.

Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, Gallì A, Porta MGD, Boveri E, Arcaini L, Candido C, Paulli M, Cazzola M.

Haematologica. 2017 Dec;102(12):2077-2085. doi: 10.3324/haematol.2017.172718. Epub 2017 Oct 5.

27.

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas.

Merli M, Frigeni M, Gotti M, Grossi P, Bruno R, Passamonti F, Arcaini L.

Hepatology. 2017 Oct;66(4):1341-1343. doi: 10.1002/hep.29198. Epub 2017 Aug 26. No abstract available.

PMID:
28378929
28.

International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.

Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV.

Autoimmun Rev. 2017 May;16(5):523-541. doi: 10.1016/j.autrev.2017.03.004. Epub 2017 Mar 7. Review.

29.

Antiviral therapies for managing viral hepatitis in lymphoma patients.

Merli M, Rattotti S, Gotti M, Arcaini L.

Expert Opin Pharmacother. 2017 Mar;18(4):363-376. doi: 10.1080/14656566.2017.1288718. Epub 2017 Feb 15. Review.

PMID:
28140702
30.

Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.

Lucioni M, Berti E, Arcaini L, Croci GA, Maffi A, Klersy C, Goteri G, Tomasini C, Quaglino P, Riboni R, Arra M, Dallera E, Grandi V, Alaibac M, Ramponi A, Rattotti S, Cabras MG, Franceschetti S, Fraternali-Orcioni G, Zerbinati N, Onida F, Ascani S, Fierro MT, Rupoli S, Gambacorta M, Zinzani PL, Pimpinelli N, Santucci M, Paulli M.

Cancer Med. 2016 Oct;5(10):2740-2755. doi: 10.1002/cam4.865. Epub 2016 Sep 26.

31.

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Merli M, Carli G, Arcaini L, Visco C.

World J Gastroenterol. 2016 Oct 14;22(38):8447-8458. Review.

32.

International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement.

Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV coauthors.

Autoimmun Rev. 2016 Dec;15(12):1145-1160. doi: 10.1016/j.autrev.2016.09.006. Epub 2016 Sep 16. Review.

33.

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O.

Blood. 2016 Nov 24;128(21):2527-2532. Epub 2016 Sep 7.

PMID:
27605512
34.

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.

Merli M, Ferrario A, Maffioli M, Olivares C, Stasia A, Arcaini L, Passamonti F.

Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14. Review.

PMID:
27416486
35.

The genetics of nodal marginal zone lymphoma.

Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D.

Blood. 2016 Sep 8;128(10):1362-73. doi: 10.1182/blood-2016-02-696757. Epub 2016 Jun 22.

36.

Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.

Gotti M, Nicola M, Lucioni M, Fiaccadori V, Ferretti V, Sciarra R, Costanza M, Bono E, Molo S, Maffi A, Croci GA, Varettoni M, Frigeni M, Pascutto C, Arcaini L, Bonfichi M, Paulli M, Cazzola M.

Hematol Oncol. 2017 Sep;35(3):296-302. doi: 10.1002/hon.2295. Epub 2016 Apr 6.

PMID:
27060262
37.

Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?

Vannata B, Arcaini L, Zucca E.

Ther Adv Hematol. 2016 Apr;7(2):94-107. doi: 10.1177/2040620715623924. Epub 2015 Dec 29. Review.

38.

Splenic marginal zone lymphoma: from genetics to management.

Arcaini L, Rossi D, Paulli M.

Blood. 2016 Apr 28;127(17):2072-81. doi: 10.1182/blood-2015-11-624312. Epub 2016 Mar 17. Review.

PMID:
26989207
39.

The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.

Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E.

J Viral Hepat. 2016 Jul;23(7):536-44. doi: 10.1111/jvh.12518. Epub 2016 Feb 29.

PMID:
26924533
40.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczkowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo ML, Arcaini L; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network.

Lancet Oncol. 2016 Mar;17(3):319-31. doi: 10.1016/S1470-2045(15)00559-8. Epub 2016 Feb 16.

PMID:
26899778
41.

Dulanermin in indolent lymphomas: an ineffective approach.

Arcaini L.

Lancet Haematol. 2015 Apr;2(4):e136-7. doi: 10.1016/S2352-3026(15)00044-7. Epub 2015 Mar 25. No abstract available.

PMID:
26687955
42.

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP.

Br J Haematol. 2016 Mar;172(5):735-44. doi: 10.1111/bjh.13897. Epub 2015 Dec 13.

43.

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, Salvi F, Arcaini L, Carella AM, Tedeschi A, Pinto A, Stelitano C, Baldini L.

Leuk Lymphoma. 2016;57(4):880-7. doi: 10.3109/10428194.2015.1091934. Epub 2016 Feb 8.

PMID:
26379040
44.

Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.

Varettoni M, Marchioni E, Bonfichi M, Picchiecchio A, Arcaini L, Arbasino C, Gotti M, Da Vià M, Delmonte M, Sciarra R, Cazzola M.

Am J Hematol. 2015 Aug;90(8):E152-3. doi: 10.1002/ajh.24059. Epub 2015 May 29. No abstract available.

45.

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.

Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.

Expert Opin Investig Drugs. 2015;24(7):897-912. doi: 10.1517/13543784.2015.1038342. Epub 2015 Apr 21. Review.

PMID:
25900401
46.

Everolimus in diffuse large B-cell lymphomas.

Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.

Future Oncol. 2015;11(3):373-83. doi: 10.2217/fon.14.264. Review.

PMID:
25675120
47.

DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.

Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F.

Blood. 2015 Mar 19;125(12):1922-31. doi: 10.1182/blood-2014-08-596247. Epub 2015 Jan 22.

48.

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.

Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA.

Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16.

49.

Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.

Arcaini L, Morello L, Tucci A, Rusconi C, Ladetto M, Rattotti S, Bonfichi M, Bottelli C, Gabutti C, Bernasconi P, Varettoni M, Gotti M, Troletti D, Guerrera ML, Fiaccadori V, Sciarra R, Ferretti VV, Alessandrino EP, Rossi G, Morra E.

Am J Hematol. 2015 Mar;90(3):230-4. doi: 10.1002/ajh.23919.

50.

The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.

Arcaini L, Rossi D, Lucioni M, Nicola M, Bruscaggin A, Fiaccadori V, Riboni R, Ramponi A, Ferretti VV, Cresta S, Casaluci GM, Bonfichi M, Gotti M, Merli M, Maffi A, Arra M, Varettoni M, Rattotti S, Morello L, Guerrera ML, Sciarra R, Gaidano G, Cazzola M, Paulli M.

Haematologica. 2015 Feb;100(2):246-52. doi: 10.3324/haematol.2014.116855. Epub 2014 Nov 7.

Supplemental Content

Loading ...
Support Center